Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07493538 · ClinicalTrials.gov registry record · Phase 2
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT07493538 is a Phase 2 study that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 132 participants.
The verdict
NCT07493538, a Phase 2 study, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.
Interventions
- DRUG Fludarabine
- DRUG Mycophenolate Mofetil
- DRUG Tacrolimus
- RADIATION Total Body Irradiation
- DRUG Treosulfan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2026-04-10 |
| Est. Completion | 2035-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07493538
The ClinicalTrials.gov registry entry for NCT07493538 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT07493538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07493538 about?
NCT07493538 is a clinical study titled "MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases". This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.
What is the current status of trial NCT07493538?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2026-04-10. Estimated completion is 2035-03.
What interventions are being tested in trial NCT07493538?
The interventions under investigation include: Fludarabine (DRUG), Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Total Body Irradiation (RADIATION), Treosulfan (DRUG).
Who is sponsoring clinical trial NCT07493538?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.